Rodin Therapeutics: Rodin Therapeutics Announces Positive Phase 1 Results Supporting Continued Development of RDN929 for Treatment of Neurologic Diseases

Compound Designed to Enhance Synaptic Integrity and Improve Learning Memory and FunctionRodin Therapeutics today announced positive Phase 1 results that provide the foundation for continued development of RDN929 a potent and selective HDACCoREST inhibitor ...